Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Sunday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Vanda Pharmaceuticals in a research note on Monday, December 23rd.

Vanda Pharmaceuticals Trading Down 1.1 %

Shares of VNDA stock opened at $4.60 on Friday. The firm’s fifty day moving average price is $4.88 and its two-hundred day moving average price is $5.07. Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75. The firm has a market capitalization of $268.22 million, a P/E ratio of -16.43 and a beta of 0.77.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now directly owns 44,857 shares in the company, valued at $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of large investors have recently made changes to their positions in VNDA. BNP Paribas Financial Markets grew its holdings in Vanda Pharmaceuticals by 1,184.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 57,393 shares in the last quarter. FMR LLC boosted its position in shares of Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after acquiring an additional 30,802 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in shares of Vanda Pharmaceuticals in the third quarter valued at about $864,000. Dimensional Fund Advisors LP increased its position in Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after acquiring an additional 292,172 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in Vanda Pharmaceuticals in the 3rd quarter worth about $143,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.